Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.Edoardo Francini, Daniel Yick Chin Heng, Francesca Montagnani et al.|Journal of Clinical Oncology|2020Cited by 1
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.Vincenzo Gennusa, Edoardo Francini, Loana Bueno Valença et al.|Journal of Clinical Oncology|2023Cited by 1
Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.Edoardo Francini, Daniel Yick Chin Heng, Francesca Montagnani et al.|Journal of Clinical Oncology|2019Cited by 0
Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study.Richard M. Lee‐Ying, Edoardo Francini, Calogero Saieva et al.|Journal of Clinical Oncology|2023Cited by 0